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High dose intravenous immunoglobulin in Rh and ABO hemolytic disease 




Hemolytic disease of the newborn (HDN) due to 
red cell alloimmunisation is an important cause of 
hyperbilirubinemia with significant morbidity in the 
neonatal period.1,2 Hemolytic disease of the 
newborn has unfortunately continued to contribute 
to perinatal and neonatal morbidity and mortality in 
developing countries.3 Traditional neonatal 
treatment of HDN consists of intensive 
phototherapy and exchange transfusion (ET). 
However, ET is a high-risk invasive procedure 
associated with a significant rate of adverse effects. 
Although the mortality rate associated with ET is 
currently reported to be <0.3% in term infants, the 
morbidity rates can reach 74% and includes 
catheter-related complications, sepsis, thrombo-
cytopenia, and hypocalcemia.4-10 Neonatal treatment 
with intravenous immunoglobulin (IVIG) has been 
suggested as an alternative therapy to ET for rhesus 
HDN.11-13 Recommendations for the routine use of 
IVIG are controversial because of various 
methodological limitations of the studies.14-17 
The aim of our study was to evaluate whether 
the use of high dose intravenous immunoglobulin 
(HD-IVIG) with intensive phototherapy in neonates 
with isoimmune hemolytic disease due to RH or 
ABO incompatibility could be effective in reducing 
the need for ET and duration of both phototherapy 




The present study is a prospective randomized 
controlled trial, conducted in the neonatal intensive 
care unit (NICU) at Gynecology and Obstetrics 
Hospital, Ain Shams University over 28 months.  
The study included 116 neonates. Inclusion criteria: 
gestational age e32 weeks, body weight e2 kg, 
positive direct Coombs' test in presence of ABO or 
Rh incompatibility, serum total bilirubin level 
indicative for phototherapy and below exchange 
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transfusion criteria, and a reticulocyte count e10%.  
Exclusion criteria: perinatal asphyxia, congenital 
malformation, severe respiratory distress, sepsis 
during hospital stay or metabolic problems. The 
study was approved by the faculty ethical 
committee and a verbal informed parental consent 
was obtained. A total of 116 neonates were 
included; 62 full term and 54 preterm neonates18 
with proven isoimmune hemolytic anemia due to 
Rh (n= 20) or ABO (n=96) incompatibility. 
 
Study design 
On study entry, infants were assigned to the IVIG 
treatment (intervention group) or placebo (control 
group). The method of treatment allocation was 
simple using coin tossing by the principal 
investigator for each trial participant. Phototherapy 
and exchange transfusion were performed 
according to the latest AAP guidelines11. All 
eligible neonates were admitted to NICU and 
received conventional intensive phototherapy using 
a white light with an intensity of 20 µW/cm/nm 
given by air shield and Ohmeda lamps, in 
combination with blue light of 30 µW/cm/nm.    
During phototherapy, extra fluids (10 mL/kg) 
were administered. In the intervention group, 
patients received conventional intensive 
phototherapy plus IVIG (supplied by Green Cross 
of South Korea) as a single dose of 1 gm/kg 
(administered within 1-4 hours of admission, over 2 
hours). Patients were closely monitored for possible 
side effects of IVIG as hypotension, tachycardia, or 
allergic reactions. 
Whenever indicated, exchange transfusion was 
performed with double-volume transfusion (160 
mL/kg) using irradiated and leukocyte-depleted 
compatible erythrocytes.  
During hospital stay, neonates were assessed 
for serum total and direct bilirubin levels every 6 
hours, and 24 hours post discharge, and daily for 
hemoglobin, reticulocyte, C-reactive protein.   
Follow up Hb level was measured at age of 1 
and 2 months. The primary outcome was the 
number of exchange transfusions per neonate. 
Secondary outcomes were duration of phototherapy 





Data were reported as means and standard 
deviations, or as numbers and percentages, as 
appropriate. Statistical analysis was performed with 
SPSS 17.0 (SPSS Inc, Chicago, IL). The Student t 
test and Mann-Whitney test were used for 
continuous variables. Chi and Fisher's exact tests 
were used for categorical variables, as appropriate. 




Our study included a total of 116 neonates; 62 full 
term and 54 preterm neonates: categorized as 20 
with Rh isoimmune hemolytic disease and 96 with 
ABO incompatibility. There were a total of 62 with 
blood group A and 34 neonates with blood group B, 
distributed between the two groups.  
There were no statistically significant 
differences between the two groups with respect to 
age, birth weight, and initial values of total serum 
bilirubin, hemoglobin, or reticulocyte count (table 
1). The rate of decline in total serum bilirubin was 
significantly higher among those who received HD-
IVIG (table 2). No immediate adverse effects 
related to IVIG were noted, including fever, allergic 
reactions, volume overload or hemolysis.  
As for the primary outcome, the number of 
those who acquired serum bilirubin levels 
indicative of ET (once or multiple) was less in the 
intervention group. The same was observed for both 
duration of phototherapy and hospitalization (tables 
3 and 4).  
Reticulocyte count dropped significantly after 
24 hours of phototherapy from 11.4±1.3 to 
5.9±1.9% in the intervention group as compared to 
a decline from 11.1±2.1 to  6.9±2.9, in the control 
group (p <0.05).  
Results were uniform across the different 
subgroups; whether preterm or full-term neonates, 
and with ABO or Rh incompatibility, with 
significant differences when intervention group was 
compared to control group with respect to outcomes 
of treatment (tables 5 and 6).  
When followed up for late anemia, none of the 
neonates in either group required top-up blood 
transfusion, and individual hemoglobin levels 
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Gestational age (weeks) 36.6±2.9 35.6±2.9 0.07 
Birth weight (kg) 3.0±0.46 2.7±0.50 2.1 
Full term/Preterm, no (%) 38/22 24/32 0.9 
Male gender, n (%) 27(45) 34(60.7) 0.89 
Age at admission (hrs) 51.5±25.4 57.8± 0.01 
Age at management (hrs), 54.3±24.9 57.8± 0.01 
Initial Hemoglobin   (gm/dl) 13.97±1.4 13.77±1.2 0.4 
Reticulocyte count (%) 11.4±1.3 11±2.1 0.27 
Total serum bilirubin (mg/dl) 16.1±4.6 16.97±3.8 0.07 
 
 










Initial total serum bilirubin (mg/dl) 16.1±4.6 16.97±3.8 0.07 
Total serum bilirubin after 6 hrs 13.9±4.6 17.1±3.3 < 0.001 
Total serum bilirubin after 12 hrs 12.9±5.2 17.4±3.3 < 0.001 
Total serum bilirubin after 18 hrs 11.9±5.1 16.9±3.4 < 0.001 
 
 





Control group  
(N=56) 
P 
Single Exchange transfusion, n (%) 9 (15) 23 (41) < 0.001 
Multiple exchange transfusion, n (%) 0 15 (26.8) < 0.001** 
Duration of hospitalization (hrs) mean +SD 27.9±18.7 103.5±30.8 < 0.001 
Duration of intensive phototherapy (hrs) mean +SD 9.97±6.2 35.5±27.3 < 0.001* 
* Mann-Whitney test; **Fisher's exact test 
 
 
Table 4. Percentage distribution of neonates who required exchange transfusion in subgroups 
 
*Fisher's exact test 
 
 
Table 5. Outcomes of treatment in Rh and ABO incompatibility subgroups 
 
Outcomes 


















Gestational age mean±SD 36.4±3.1 35.5±3.3 0.53 36.7±2.8 36.2±2.9 0.42 
Birth weight mean±SD 2.9±0.6 2.8±0.7 0.72 2.9±0.5 2.7±0.45 0.037 
Single Exchange transfusion, n (%) 3 (25%) 7 (87.5%) <0.001* 6 (12.5%) 16 (33.3%) <0.01** 
Multiple exchange transfusion, n (%) 0 3 (37.5%) <0.01* 0 12 (25%) <0.001** 
Duration of hospitalization (hrs) mean±SD 25±18.1 99±35.6 <0.001* 28.6±18.9 104.3±30.2 <0.001 
Duration of intensive physiotherapy (hrs) mean±SD 11.5±9.4 38.3±28.9 <0.001* 9.6±5.2 35±27.3 <0.001* 








Rh incompatibility (N=20) 3/12 (25%) 8/8 (100%) <0.001* 
ABO incompatibility (N=96) 6/48 (12.5%) 30/48 (62.5%) <0.001 
Full term (N= 62) 6/38 (15.8%) 16/24 (66.7%) >0.05 
Preterm (N=54) 3/22 (13.6%) 22/32 (68.8%) <0.001* 
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Table 6. Outcomes of treatment in full term and preterm subgroups 
 
Outcomes 


















Gestational age 38.6±1.1 38.8±0.9 0.34 33.2±1.1 33.2±0.8 0.89 
Birth weight 3.2±0.3 3.2±0.2 0.78 2.3±0.2 2.3±0.14 0.24 
Single Exchange transfusion, n (%) 6 (15.8%) 10 (41.6%) <0.05* 3 (13.6%) 13 (40.6%) <0.05** 
Multiple exchange transfusion, n (%) 0 6 (25%) <0.01* 0 9 (28.1%) <0.01** 
 
 
Table 7. Serial mean Hemoglobin levels during the study period 
 
Variables Intervention (n) mean ±SD Control (n) mean ±SD P 
Hb (gm/dl) at Hour 12 (60 ) 13.976±1.382 (56 )13.784±1.242 0.437 
Hb (gm/dl) at Hour 24 (60) 13.813±1.365 (55)14.024±1.996 0.42 
Hb (gm/dl) at Hour 36 (36) 13.972±1.187 (52)14.348±1.105 0.248 
Hb (gm/dl) at Hour 48 (27 ) 14.256±0.686 (46 )14.317±1.166 0.831 
Hb (gm/dl) at age of one month (60) 13.365±1.647 (56)14.232±1.373 0.019 




The mainstay of treatment of isoimmune hemolytic 
disease is intensive phototherapy with exchange 
transfusion if the total serum bilirubin despite of 
phototherapy, still approaches a level considered to 
cause a risk of bilirubin encephalopathy. Neonatal 
treatment with intravenous immunoglobulin (IVIG) 
has been suggested as an alternative therapy to 
exchange transfusion for HDN.  
With the wide use of anti-D to prevent Rh 
hemolytic disease, other blood group 
incompatibilities now assume a major role in the 
causation of neonatal hyperbilirubinemia which 
may require exchange transfusion19, 20. Hence, over 
28 months, we were able to include only 20 
neonates with Rh but good number of ABO 
incompatibility (96) which shows that ABO 
hemolytic disease is an important cause of 
significant hyperbilirubinemia in Egyptian 
neonates. Our study is the only randomized 
controlled trial to date to include full and preterm 
neonates and both Rh and ABO incompatibility. 
Our results support the recommendation of the 
American Academy of Pediatrics and many other 
studies to give IVIG in rhesus and ABO isoimmune 
hemolytic disease.11,16,21-23 Our study results showed 
that administering IVIG has resulted in significantly 
fewer neonates requiring exchange transfusion 
compared to those who received phototherapy 
alone. The significant reduction in the need for 
exchange transfusion was consistent among 
different subgroups; Rh and ABO incompatibility, 
and full term and preterm neonates. The mechanism 
by which IVIG is thought to reduce the degree of 
hemolysis is by blocking the reticuloendothelial FC 
receptor sites and hence preventing the 
extravascular destruction of neonatal red blood cells 
by transplacentally acquired maternal antibodies.15 
This competitive action of IVIG with isoantibodies 
has led to the suggestion that, in order for IVIG to 
be effective it must be administered as soon as the 
diagnosis of isoimmune hemolytic anemia is 
made.14 IVIG might increase IgG catabolism, 
resulting in a shorter half-life of antibodies 
(including anti-Rh antibodies). A third hypothesis is 
the presence of antiidiotypic antibodies in IVIG 
neutralizing anti-Rh antibodies.16, 24-26 
The use of IVIG to avoid exchange transfusion 
in HDN was reported in many studies with different 
methodology in terms of dose and frequency of 
administration of IVIG, type of hemolytic disease 
and other inclusion criteria and hence the results 
were conflicting and variable. A single dose of 0.5 
gm/kg reduced the need for exchange transfusion 
without producing immediate adverse effects in 
term neonates with ABO12 or Rh hemolytic 
disease.27 Low-dose IVIG (0.5gm/kg) was as 
effective as high dose (1gm/kg) in reducing the 
duration of phototherapy and hospital stay, but less 
effective in avoiding exchange transfusion in Rh 
hemolytic disease of newborn.23 Tanyer et al,28 
looked at single versus multiple dose IVIG, and 
found that multiple dose IVIG resulted in a greater 
percentage reduction in the need for exchange 
transfusion in ABO and Rh HDN. Meanwhile, 
IVIG therapy (1gm/kg), single or multiple doses, 
did not obviate the need for exchange transfusion 
and erythrocyte transfusion nor shorten 
hospitalization time when used in combination with 
light emitting diode phototherapy in the treatment 
IV immunoglobulin in neonatal hemolytic disease 
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of ABO hemolytic jaundice in neonates.29 
Nonspecific human immunoglobulin as single dose 
of 0.5gm/kg was not effective in preventing the 
need for exchange transfusion in neonates with 
rhesus hemolytic disease.30 Prophylactic IVIG (0.75 
gm/kg) did not reduce the need for exchange 
transfusion nor the rates of other adverse neonatal 
outcomes.31 
Our study showed significant decrease in mean 
duration of intensive phototherapy which is 
consistent with other studies12,16,32  This difference 
might reflect the continuing effect of IVIG in 
controlling the hemolytic process and hence the 
need for longer use of phototherapy. Minimizing 
phototherapy exposure will decrease its associated 
hazards such as retinopathy, skin rash and frequent 
loose green bowel motions and bronze baby 
syndrome.23 In another study, IVIG in a dose of 
0.5gm/kg for 2 days administered to 8 Rh 
isoimmunized babies was effective in reducing the 
need for exchange transfusion but duration of 
phototherapy was comparable in IVIG and non 
IVIG groups.21 
We noticed significant reduction in the length 
of hospital stay when IVIG was administered. Mean 
hospital stay was measured solely for the duration 
needed to treat the hemolytic disease, as  neonates, 
who developed clinical sepsis, needing to extend 
their length of stay to complete the antibiotic 
course, were excluded from the study.  This was the 
main reason why the length of stay in our babies 
who received IVIG was significantly shorter in 
comparison with other studies which reported 
significant reduction in the length of hospital stay 
when IVIG was administered.16, 32 This signifies the 
value of IVIG in decreasing the hospital stay 
hazards, thereby ameliorating nosocomial infections 
and decreasing time where the infant is separated 
from his mother to promote and support successful 
breastfeeding.23 
Our neonates tolerated well the high dose of 
IVIG without apparent drug-related adverse events 
as reported by others.12,16,32 Necrotizing entero-
colitis in newborns with hemolytic disease was 
reported as a complication of treatment with 
IVIG.13,33 Transfusions for late anemia were 
reported to be increased in babies who received 
IVIG in some studies.14-16 This was explained by 
the fact that antibody-sensitized neonatal 
erythrocytes bind to the Fc sites on the surface of 
the reticuloendothelial cells which have become 
free after the effect of IVIG had faded, causing late 
hemolysis. In our patients, severe late anemia 
requiring up blood transfusion was not encountered. 
 
CONCLUSION 
We conclude that a single high dose of IVIG could 
be a safe and effective therapy for reducing the 
need for exchange transfusion and duration of 
phototherapy and hospital stay in significant 
hyperbilirubinemia of Rh and ABO hemolytic 
disease of neonates. The financial saving from 
shortened inpatient stay and duration of 
phototherapy offsets the cost of IVIG. 
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